Article Text
Statistics from Altmetric.com
Description
A 30-year-old woman, treated with immunomodulators due to an ulcerative colitis, presented to our hospital with an accidental finding of bilateral axillary polyadenopathies on echography in a presurgery breast augmentation procedure. The patient claimed no symptoms, and the fact that she lived with cats was the only epidemiological data of interest. A physical examination revealed painless and superficial adenopathies approximately 1 cm large on both the left supraclavicular fossa and bilateral axillary cavity. Three tattoos were found on the patient (figure 1).
Several laboratory tests were performed with the following results: CRP 11.8 mg/L and ESR 25 mm/h, with autoimmunity, serologies (HBV, HCV, HIV, CMV, EBV, toxoplasma, syphilis and Bartonella henselae) and IGRA tests all negative. A thoracoabdominal CT confirmed the subcentimetric adenopathies (left supraclavicular and bilateral axillary), which suggested lymphocyte proliferation disorder as the most likely diagnosis. Positron emission tomography revealed multiple hypermetabolic adenopathies with low uptake, so low‐grade lymphoproliferative syndrome could not be ruled out (figure 1).
Given the lack of a definitive diagnosis, the fact that low levels of FDG uptake cannot completely dismiss malignancy, the use of immunosuppressive therapies, and the emotional distress showed by the patient, we asked the surgery department to perform an exeresis of the most accessible one (the left supraclavicular). Its dark colour caught their attention. Once the sample was processed, the department of pathology asked whether the patient had any tattoos.
A diagnosis of pigment-related lymphadenopathy was made (figure 2).
Our aim with this case is to draw attention to the potential adverse effects of having tattoos. This aesthetic procedure is more and more common in our society (about 60 million people in Europe and 16% of the population in the USA have at least one tattoo).1 However, there is widespread lack of knowledge regarding how ink degrades under the skin as well as the effects of such degradation. The biggest problem may arise over the long term, as some patients have had reactions months or years following the procedure (it was 6 years in the case of our patient).
Pigment accumulates in the dermis and spreads across the intracellular space, causing haemorrhage, necrosis and inflammation that results in phagocytosis by skin macrophages. Macrophages reach the lymph nodes, where inflammatory reactions can take place and, in many cases, last long after the tattoo has been removed. Sometimes this can be revealed subclinically (autopsies of tattooed patients sometimes reveal the existence of regional adenopathies with pigments).1
In some cases, malignant skin tumours may develop within the tattoos. The pigments used can degrade with exposure to light, releasing potentially carcinogenic substances via haematogenous spread.2 It can be difficult to differentiate a neoplastic process from pigment-related lymphadenopathy (in tattooed oncological patients can be mistaken as neoplastic progression). PET/CT can help to avoid unnecessary biopsies. The results were doubtful in the case of our patient, although false positives have been described.3 Histological confirmation can be necessary under such circumstances. Our differential diagnosis was established with a lymphocyte proliferation, and the final diagnosis was anatomopathological.
Learning points
Pigment lymphadenopathy must be part of the differential diagnosis for tattooed patients with adenopathies of unknown aetiology in draining lymph nodes.
Even though positron emission tomography/CT can produce false-positives, its proper interpretation must be carefully considered to avoid unnecessary exploration.
A histological diagnosis is not necessary in every patient, but in the event of doubt a differential diagnosis of malignant entities must always be histological.
Footnotes
Contributors CPA: discuss planning, reporting, follow-up of the case, conception and design, acquisition of informed consent, writing the case and cover letter. OV-G: discuss planning, reporting, follow-up of the case and writing the case. RGC: discuss planning, reporting, follow-up of the case. CDH: discuss planning, follow-up of the case, anatomopathological analysts and take the pictures.
Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.
Competing interests None declared.
Provenance and peer review Not commissioned; externally peer reviewed.
Patient consent for publication Obtained.